Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 11/20 | 0.48 |
| ▸ | BACE1 | P56817 | 8/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | HRH1 | P35367 | 3/20 | 0.43 |
| ▸ | CCR3 | P51677 | 3/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7488216 | 0.89 | ACHE (0.52) | ACHEBACE1MEN1KMT2ASIGMAR1 | |
| SCHEMBL13888633 | 0.81 | MEN1 (0.51) | ACHEBACE1MEN1KMT2ASIGMAR1 | |
| SCHEMBL13888638 | 0.77 | MEN1 (0.49) | ACHEBACE1MEN1KMT2ASIGMAR1 | |
| SCHEMBL4032279 | 0.76 | MEN1 (0.44) | MEN1KMT2ASIGMAR1HRH1CCR3 | |
| SCHEMBL4033634 | 0.75 | MEN1 (0.47) | MEN1KMT2ASIGMAR1HRH1CCR3 | |
| SCHEMBL6394743 | 0.75 | CCR3 (0.47) | HRH1CCR3 | |
| SCHEMBL13888623 | 0.75 | MEN1 (0.54) | ACHEBACE1MEN1KMT2ASIGMAR1 | |
| SCHEMBL13888568 | 0.74 | SYK (0.41) | ACHEBACE1 | |
| SCHEMBL6396292 | 0.73 | HRH1 (0.53) | HRH1CCR3 | |
| SCHEMBL6397083 | 0.73 | HRH1 (0.53) | HRH1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1212299-B1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LTD (GB) | 2009-04-08 | — | — | EP | disclosed |
| US-20050250792-A1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | MERRILL LYNCH CAPITAL, A DIVISION OF MERRILL LYNCH BUSINESS FINANCIAL SERVICES, INC. AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | disclosed |
| US-6903085-B1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | ASTRAZENECA, AB (CH) | 2005-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250792-A1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | CXCR4, CXCR1, CXCR3 | ACHE 2721/4885BACE1 3062/4885MEN1 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.